Candesartan Attenuates Cisplatin-Induced Lung Injury by Modulating Oxidative Stress, Inflammation, and TLR-4/NF-κB, JAK1/STAT3, and Nrf2/HO-1 Signaling

• Auteurs principaux: Ahmed M. Atwa (Auteur), Omnia A. M. Abd El-Ghafar (Auteur), Emad H. M. Hassanein (Auteur), Somya E. Mahdi (Auteur), Ghadir A. Sayed (Auteur), Reem S. Alruhaimi (Auteur), Haifa A. Alqhtani (Auteur), Mohammed F. Alotaibi (Auteur), Ayman M. Mahmoud (Auteur)
• Format: Livre
• Publié: MDPI AG, 2022-10-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Cisplatin (CIS) is an effective chemotherapeutic agent against different cancers. The use of CIS is associated with acute lung injury (ALI) and other adverse effects, and oxidative stress and inflammation were implicated in its toxic effects. Candesartan (CAN), an angiotensin II (Ang II) receptor bl...